PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 21, 2013Cardiology Journal130 citationsOpen Access

Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up

AEAli ElitokFÖFahrettin ÖzAÇAhmet Yaşar Çizgici

Key Result

Carvedilol preserved peak systolic strain compared to the control group, indicating a protective effect against anthracycline-induced cardiotoxicity in breast cancer patients during 6 months of therapy.

Study Design

Type

RCT (n=80)

Blinding

null

Randomization

Computer-generated sequence

Multicenter

No

Structured PICO

Does carvedilol prevent anthracycline-induced cardiotoxicity assessed by strain imaging in female patients with breast cancer?

P
Population
80 female patients with breast cancer and anticipated anthracycline therapy, single-center (Turkey). Key exclusion criteria: previous chemotherapy or radiotherapy; cardioprotective drug use; presence of any cardiac disease detected upon baseline evaluation; history of chronic disease (diabetes, hypertension, chronic renal or hepatic failure); and any contraindication to carvedilol use.
I
Intervention
Carvedilol 12.5 mg oral prior to computed tomography, followed by an oral maintenance dose of 12.5 mg daily for 6 months during chemotherapy.
C
Comparator
Control group receiving no drug that could have a cardioprotective effect (open-label, no placebo).
O
Outcome
Left ventricular systolic function assessed by 2D strain imaging (peak systolic strain and strain rate) and conventional echocardiography (LVEF, FS) at 6 months post anthracycline treatment.surrogate

Carvedilol administration during anthracycline therapy preserves longitudinal left ventricular systolic function as detected by strain imaging, suggesting a protective effect against early subclinical cardiotoxicity.

Main Result

Effect estimate: null (95% CI null)

p-value: p=<0.005

Limitations

  • Open-label design
  • Relatively small sample size
  • open label design
  • relatively small sample size
  • short follow-up

Abstract

These results indicate that carvedilol has a protective effect against the cardiotoxicity induced by ANT.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Elitok et al. (2013) conducted an RCT in Breast cancer (n=80). Carvedilol vs. Placebo was evaluated on Change in peak systolic strain and strain rate (null, 95% CI null, p=<0.005). Carvedilol preserved peak systolic strain compared to the control group, indicating a protective effect against anthracycline-induced cardiotoxicity in breast cancer patients during 6 months of therapy.

synapsesocial.com/papers/696d73620860973dc1fe7ad8https://doi.org/10.5603/cj.a2013.0150
Ask AI
Helpful
Bookmark
Share
View Full Paper